PF-04634817

oral CCR2/5 receptor dual antagonist PF-04634817

Also Known As:

1,5-Anhydro-2,3-dideoxy-3-(((1R,3S)-3-isopropyl-3-(((1S,4S)-5-(6-(trifluoromethyl)-4-pyrimidinyl)-2,5-diazabicyclo(2.2.1)hept-2-yl)carbonyl)cyclopentyl)amino)-4-O-methyl-D-erythro-pentitol

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - PF-04634817: 2
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - Azabicyclo Compounds
      - PF-04634817: 2
Organic Chemicals: 133
- Aza Compounds: 3
  - Azabicyclo Compounds
    - PF-04634817: 2

Experts

1.	Gale, Jeremy D: 2 articles (11/2018 - 01/2018)
2.	Gilbert, Steven: 2 articles (11/2018 - 01/2018)
3.	Perros-Huguet, Christelle: 2 articles (11/2018 - 01/2018)
4.	Blumenthal, Samuel: 1 article (11/2018)
5.	Elliott, Tom: 1 article (11/2018)
6.	Goteti, Kosalaram: 1 article (11/2018)
7.	Pergola, Pablo E: 1 article (11/2018)
8.	Scheele, Wim: 1 article (11/2018)
9.	Berger, Brian: 1 article (01/2018)
10.	Girgenti, Douglas: 1 article (01/2018)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 11/01/2018 - "We evaluated the efficacy of PF-04634817 compared with matching placebo for reduction of albuminuria after 12 weeks of treatment in subjects with type 2 diabetes who received standard of care (SOC; angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy), in a randomized, double-blind, placebo-controlled, parallel-group phase 2 study. "
2.	Albuminuria 11/01/2018 - "Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy." 11/01/2018 - "We evaluated the efficacy of PF-04634817 compared with matching placebo for reduction of albuminuria after 12 weeks of treatment in subjects with type 2 diabetes who received standard of care (SOC; angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy), in a randomized, double-blind, placebo-controlled, parallel-group phase 2 study. "
3.	Macular Edema 01/01/2018 - "A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema."
4.	Diabetic Nephropathies (Diabetic Nephropathy) 11/01/2018 - "PF-04634817 is a dual chemokine CCR2/5 receptor antagonist that is being developed for the treatment of diabetic nephropathy. " 11/01/2018 - "Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy."

Related Drugs and Biologics

1.	Angiotensin Receptor Antagonists
2.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
3.	Chemokine Receptors
4.	Chemokines
5.	Ranibizumab (Lucentis)

Related Therapies and Procedures

1.	Therapeutics